Schizophrenia Clinical Trials in Chicago, Illinois

20 studies are recruiting for schizophrenia in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

   The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Local Institution - 0067, Chicago, Illinois

   Locations

   59 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07686263 on ClinicalTrials.gov

2. 52-week Open Label Safety-Tolerability Study

   Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Pillar Clinical Research, Chicago, Illinois

   Locations

   23 in total

   Run by

   LB Pharmaceuticals Inc.

   See if you can join NCT07369154 on ClinicalTrials.gov

3. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

   The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.

   Stage

   Phase 3

   Ages

   13 to 17

   Site

   EmVenio Research Center - Prime Healthcare, Chicago, Illinois

   Locations

   38 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07288567 on ClinicalTrials.gov

4. A Study of Brenipatide in Adult Participants With Schizophrenia

   The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment pe…

   Stage

   Phase 2

   Ages

   18 to 55

   Site

   Re:Cognition Health - Chicago, Chicago, Illinois

   Locations

   103 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07410507 on ClinicalTrials.gov

5. A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT

   A study to evaluate the safety, tolerability, and PK of an injectable form of KarXT in participants with schizophrenia

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   Uptown Research Institute, Chicago, Illinois

   Locations

   8 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07061288 on ClinicalTrials.gov

6. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

   ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Clinical Site, Chicago, Illinois

   Locations

   42 in total

   Run by

   MapLight Therapeutics

   See if you can join NCT07459647 on ClinicalTrials.gov

7. A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

   The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively

   Stage

   Phase 3

   Ages

   5 to 17

   Site

   EmVenio Research Center - Prime Healthcare, Chicago, Illinois

   Locations

   91 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07424404 on ClinicalTrials.gov

8. A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

   The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study/assessments. It will also assess how safe and tolerable aticaprant is when compared with placebo in participants with schizophrenia.

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   Uptown Research Institute, Chicago, Illinois

   Locations

   8 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07615426 on ClinicalTrials.gov

9. Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

   To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine

   Stage

   Phase 3

   Ages

   10 to 17

   Site

   Alkermes Investigator Site, Chicago, Illinois

   Locations

   47 in total

   Run by

   Alkermes, Inc.

   See if you can join NCT05303064 on ClinicalTrials.gov

10. A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

    Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Uptown Research Institute, Chicago, Illinois

    Locations

    73 in total

    Run by

    Otsuka Pharmaceutical Development & Commercialization, Inc.

    See if you can join NCT06894212 on ClinicalTrials.gov

11. Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

    The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia

    Stage

    Phase 2

    Ages

    18 to 65

    Site

    Uptown Research Institute LLC, Chicago, Illinois

    Locations

    16 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT07467993 on ClinicalTrials.gov

12. Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

    This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Pillar Clinical Research, Chicago, Illinois

    Locations

    13 in total

    Run by

    LB Pharmaceuticals Inc.

    See if you can join NCT07363577 on ClinicalTrials.gov

13. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

    This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Chicago, Illinois

    Locations

    57 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT07114874 on ClinicalTrials.gov

14. A Study to Evaluate the Effect of KarXT on Urological Safety

    The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.

    Stage

    Phase 4

    Ages

    18 to 65

    Site

    Uptown Research Institute, Chicago, Illinois

    Locations

    13 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07221877 on ClinicalTrials.gov

15. CLOZAPINE Response in Biotype-1

    The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as ps…

    Stage

    Phase 4

    Ages

    18 to 60

    Site

    University of Chicago, Chicago, Illinois

    Locations

    5 in total

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT04580134 on ClinicalTrials.gov

16. Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

    The Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS) study aims to understand the early stages of psychotic disorders like Schizophrenia, Schizoaffective Disorder, and Bipolar I Disorder. It involves gathering mental health information, brain scans (MRI), eye movement …

    Stage

    Not phased

    Ages

    18 to 40

    Site

    University of Chicago Medical Center, Chicago, Illinois

    Locations

    6 in total

    Run by

    Beth Israel Deaconess Medical Center

    See if you can join NCT06740383 on ClinicalTrials.gov

17. NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

    The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Chicago, Illinois

    Locations

    21 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT06963034 on ClinicalTrials.gov

18. Randomized Withdrawal Study in Patients With Schizophrenia

    The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Vanda Investigational Site, Chicago, Illinois

    Locations

    22 in total

    Run by

    Vanda Pharmaceuticals

    See if you can join NCT06961968 on ClinicalTrials.gov

19. Study of ALTO-101 in Patients With Schizophrenia

    This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerabil…

    Stage

    Phase 2

    Ages

    21 to 55

    Site

    Site 5056, Chicago, Illinois

    Locations

    14 in total

    Run by

    Alto Neuroscience

    See if you can join NCT06502964 on ClinicalTrials.gov

20. Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

    This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period o…

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Reviva site, Chicago, Illinois

    Locations

    18 in total

    Run by

    Reviva Pharmaceuticals

    See if you can join NCT05184335 on ClinicalTrials.gov